AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)

Shots:

• The P-III THEMIS study involves assessing of Brilinta (ticagrelor) + aspirin vs aspirin monothx in patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior myocardial infarction or stroke
• The P-III study resulted in meeting its 1EPs with the reduction in the composite of major adverse cardiovascular events (MACE) compared to aspirin alon
• Brilinta (ticagrelor) is an oral P2Y12 receptor antagonist inhibits platelet activation, when administered in combination with aspirin prevents atherothrombotic events in adults with ACS

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter